TOWA Pharmaceutical Co (FRA:6QC) EBIT: €90 Mil (TTM As of Mar. 2026)


FRA:6QC TOWA Pharmaceutical Co Ltd FRA:6QC
87 GF Score
Price €19.60
GF Value €17.85
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is TOWA Pharmaceutical Co EBIT?

TOWA Pharmaceutical Co FRA:6QC -3.92% 87 EBIT is €90 Mil as of Mar. 2026. GuruFocus rates FRA:6QC with a GF Score™ of 87/100 and a GF Value™ of €17.85 (Fairly Valued). The stock has 5 warning signs investors should review.

TOWA Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-56 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €90 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TOWA Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 was 3.56%. TOWA Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -12.32%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TOWA Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.50%.


TOWA Pharmaceutical Co  (FRA:6QC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TOWA Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=78.756 * ( 1 - 0% )/( (2338.005 + 2088.333)/ 2 )
=78.756/2213.169
=3.56 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2677.797 - 121.69 - ( 218.102 - max(0, 511.173 - 1449.163+218.102))
=2338.005

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2590.867 - 255.565 - ( 246.969 - max(0, 528.035 - 1457.321+246.969))
=2088.333

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

TOWA Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-222.516/( ( (938.121 + max(896.16, 0)) + (930.197 + max(848.963, 0)) )/ 2 )
=-222.516/( ( 1834.281 + 1779.16 )/ 2 )
=-222.516/1806.7205
=-12.32 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(385.966 + 661.554 + 183.541) - (121.69 + 0 + 213.211)
=896.16

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(344.964 + 672.806 + 192.582) - (255.565 + 0 + 105.824)
=848.963

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TOWA Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=89.566/1991.043
=4.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TOWA Pharmaceutical Co EBIT Related Terms


TOWA Pharmaceutical Co EBIT Historical Data

* Premium members only.

The historical data trend for TOWA Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TOWA Pharmaceutical Co EBIT Chart

TOWA Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 172.11 36.62 156.01 173.49 84.09

TOWA Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.81 27.00 49.58 68.62 -55.63

FRA:6QC vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, TOWA Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TOWA Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TOWA Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TOWA Pharmaceutical Co's EV-to-EBIT falls into.


FRA:6QC
87GF Score
TOWA Pharmaceutical Co Ltd FRA:6QC
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TOWA Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €90 Mil mean?
TOWA Pharmaceutical Co (FRA:6QC) has a EBIT of €90 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TOWA Pharmaceutical Co.
Is TOWA Pharmaceutical Co's EBIT too high?
TOWA Pharmaceutical Co's current EBIT is €90 Mil. Overall, TOWA Pharmaceutical Co has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TOWA Pharmaceutical Co's EBIT compare to ZTS?
TOWA Pharmaceutical Co's EBIT of €90 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TOWA Pharmaceutical Co. TOWA Pharmaceutical Co's current EBIT is €90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TOWA Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co (FRA:6QC) is currently considered Fairly Valued. The stock's GF Value™ is €17.85, compared to a current price of €19.60 — trading 9.8% above its estimated fair value. The current EBIT is €90 Mil. TOWA Pharmaceutical Co's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For TOWA Pharmaceutical Co (FRA:6QC), the current EBIT is €90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TOWA Pharmaceutical Co (FRA:6QC) Overvalued in 2026?

Based on GuruFocus' analysis, TOWA Pharmaceutical Co stock appears to be overvalued. The current stock price of €19.60 is trading 9.8% above its estimated GF Value™ of €17.85. GuruFocus considers TOWA Pharmaceutical Co to be Fairly Valued.

Key valuation signals for FRA:6QC:

  • EBIT: €90 Mil
  • GF Value™: €17.85 vs. price of €19.60 (9.8% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the FRA:6QC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TOWA Pharmaceutical Co Business Description

Other Exchanges 4553:Japan
Address 2-11, Shinbashi-cho, Kadoma, Osaka, JPN, 571-8580
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
87GF Score

Get the complete analysis for FRA:6QC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.60
Price
€17.85
GF Value